Rothwell Figg’s Emerging Companies Blog, RF EMerge, is a resource for early-stage companies providing content on common challenges they face, pertinent industry trends and analysis, and key legal developments affecting emerging companies. The content on the site is generated and edited by Rothwell Figg attorneys who serve such growth companies in our Emerging Companies practice team. To learn more, please visit www.RFEMerge.com.
IP Watchdog.com, the largest online intellectual property publication in the world and a leading source for news, information, analysis, and commentary in the patent and innovation industries published an article authored by partner Jennifer Maisel…
Partner Jess Collen published an article titled "Is 'Meta' Really A Better Trademark? Don't Let 'Facebook' Be Your Playbook" on Forbes.com. Mr. Collen is a contributor on the site and regularly writes on trademarks, branding, copyright, advertising,…
- Rothwell Figg’s Christopher Ott Updates Article in ICLG Cybersecurity 2022 on Data Security and Privacy Lapses Leading to Personal Liability
Partner Christopher Ott updated the article he previously wrote titled “Phantom Responsibility: How Data Security and Privacy Lapses Lead to Personal Liability for Officers and Directors" for the International Comparative Legal Guide to: Cybersecurity 2022,…
- Steven Lieberman and Jennifer Nock Contribute to The Sedona Conference WG10 Commentary on Patent Litigation Best Practices: Unique Aspects of Biopharma Litigation Chapter
Rothwell Figg partners Steve Lieberman and Jennifer Nock, who are members of The Sedona Conference Working Group 10 on Patent Litigation Best Practices (WG10), played a leading role in authoring and bringing to publication for…
- The mRNA IP and Competitive Landscape, A Three Part Series
Partner Daniel Shores, associate Dylan Haversack, and patent agent Andrew Storaska, Ph.D. authored a three-part series titled "The mRNA IP and Competitive Landscape" for IPWatchdog.com, the largest online intellectual property publication in the world and a…
- View All Publications
Rothwell Figg’s blog, Privacy Zone, offers insights on developments in privacy, data protection, and cybersecurity laws, regulations, cases, and news in the U.S. and internationally. The blog is authored by attorneys in the firm’s Privacy, Data Protection, and Cybersecurity practice group, all of whom are technology-focused advisors and litigators as well as Certified Information Privacy Professionals in the United States (CIPP/US). Combined with technical backgrounds and industry experience in computer science, artificial intelligence/machine learning, Internet of Things (IoT), cryptocurrency, blockchain, fintech, bioinformatics, connected device technology, wearables, big data, and adtech, we are uniquely qualified to assess and address the issues at the forefront of these evolving areas of law. To learn more, please visit www.theprivacylaw.com.
BiosimilarsIP.com features articles, updates, and analysis on regulatory issues, legal decisions, and other news related to biologics and biosimilars under the Biologics Price Competition and Innovation Act (BPCIA). The posts, authored and edited by attorneys in the firm’s Biologics and Biosimilars practice group, track regulatory issues and events, provide analysis of legal decisions from federal courts and from the Patent Trial and Appeal Board, and offer updates on current news and events related to biologics and biosimilars. Our team understands the manufacturing, regulatory, and legal requirements of the field, and has the experience and the technical knowledge to handle the most sophisticated matters, including issues related to regulatory approval, securing patent rights, counseling and opinions, post-grant challenges, and asserting or defending against patents in litigation. To learn more, please visit www.BiosimilarsIP.com.
Authored and edited by attorneys in the firm’s Post-Grant Trial practice group, PTABLaw.com provides updates, articles, and analysis about the Patent Trial and Appeal Board (PTAB), the Court of Appeals for the Federal Circuit, and the America Invents Act. Our group has considerable experience handling inter partes review (IPR), covered business method (CBM) review, and post-grant review (PGR) proceedings before the PTAB. Our depth of knowledge and expertise with handling matters before the PTAB is unique, as many of the attorneys in our group have substantial experience in handling interference proceedings and reexaminations, and in prosecuting applications before the Office, as well as extensive litigation experience in the federal courts. To learn more, please visit www.PTABLaw.com.